Is lithium a neuroprotective agent?

Annals of Clinical Psychiatry

Volumn 27, Issue 1, 2015, Pages 49-54

  Vo, Thuy M ^a   Perry, Paul ^a   Ellerby, Michael ^a   Bohnert, Kimberly ^a  

^a TOURO UNIVERSITY CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; GLYCOGEN SYNTHASE KINASE 3; LITHIUM; N ACETYLASPARTIC ACID; NEUROPROTECTIVE AGENT; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE; LITHIUM DERIVATIVE;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COGNITION; COGNITIVE DEFECT; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MEMORY DISORDER; META ANALYSIS (TOPIC); NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHORT TERM MEMORY; SYSTEMATIC REVIEW; ANIMAL; DRUG EFFECTS;

ALZHEIMER DISEASE; ANIMALS; COGNITION; HUMANS; LITHIUM COMPOUNDS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 84942851066     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Meijer L, Flajolet M, Greengard P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci. 2004;25:471-480.
2. Camins A, Verdaguer E, Junyent F, et al. Potential mechanisms involved in the prevention of neurodegenerative diseases by lithium. CNS Neurosci Ther. 2009;15:333-344.
3. Chiu CT, Wang Z, Hunsberger JG, et al. Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev. 2013;65:105-142.
4. Shin HW, Chung JS. Drug-induced parkinsonism. J Clin Neurol. 2012;8:15-21.
5. Reches A, Tietler J, Lavy S. Parkinsonism due to lithium carbonate poisoning. Arch Neurol. 1981;38:471.
6. Senturk V, Goker C, Bilgic A, et al. Impaired verbal memory and otherwise spared cognition in remitted bipolar patients on monotherapy with lithium or valproate. Bipolar Disord. 2007;9(suppl 1):136-144.
7. Wingo AP, Wingo TS, Harvey PD, et al. Effects of lithium on cognitive performance: A meta-analysis. J Clin Psychiatry. 2009;70:1588-1597.
8. Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's Disease. Curr Alzheimer Res. 2013;10:104-107.
9. Hansen HE, Amdisen A. Lithium intoxication: Report of 23 cases and review of 100 cases from literature. Q J Med. 1978;47:123-144.
10. Zhu Y, Zhang J, Zeng Y. Overview of tyrosine hydroxylase in Parkinson's disease. CNS Neurol Disord Drug Targets. 2012;11:350-358.
11. Arraf Z, Amit T, Youdim MB, et al. Lithium and oxidative stress lessons from MPTP model of Parkinson's disease. Neurosci Lett. 2012;516:57-61.
12. Castro AA, Ghisoni K, Latini A, et al. Lithium and valproate prevent olfactory and short-term memory impairments in the intranasal 1-methyl-4-phenyl- 1, 2, 3, 6tetrahydropyridine (MPTP) rat model of Parkinson's disease. Behav Brain Res. 2012;229:208-215.
13. Prasad KN, Cole WC, Kumar B. Multiple antioxidants in prevention and treatment of Parkinson's disease. J Am Coll Nutr. 1999;18:413-423.
14. de Vasconcellos AP, Nieto FB, Crema LM, et al. Chronic lithium treatment has antioxidant properties but does not prevent oxidative damage induced by chronic variate stress. Neurochem Res. 2006;31:1141-1151.
15. Yong Y, Ding H, Fan Z, et al. Lithium fails to protect dopaminergic neurons in the 6-OHDA model of Parkinson's disease. Neurochem Res. 2011;36:367-374.
16. Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839-840.
17. Kim JH, Rane A, Lussier S, et al. Lithium protects against oxidative stress-mediated cell death in alpha synuclein-overexpressing in vitro and in vivo models of Parkinson's disease. JNR. 2011;89:1666-1675.
18. Schuff N, Meyerhoff DJ, Mueller S, et al. N-acetylaspartate as a marker of neuronal injury in neurodegenerative disease. Adv Exp Med Biol. 2006;576:241-262.
19. Sassi RB, Stanley JA, Axelson D, et al. Reduced NAA levels in the dorsolateral prefrontal cortex of young bipolar patients. Am J Psychiatry. 2005;162:2109-2115.
20. Ryves WJ, Harwood AJ. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun. 2001;280:720-725
21. Hajek T, Bauer M, Pfennig A, et al. Large positive effect of lithium on prefrontal cortex N-acetylaspartate in patients with bipolar disorder: 2-centre study. J Psychiatry Neurosci. 2012;37:185-192.
22. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res. 2007;32:577-595.
23. Hampel H, Ewers M, Bürger K, et al. Lithium trial in Alzheimer's disease: A randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry. 2009;70:922-931.
24. Forlenza OV, Diniz BS, Radanovic M, et al. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: Randomised controlled trial. Br J Psychiatry. 2011;198:351-356.
25. Shen HC, Li JY, Lo YK. Lithium intoxication-induced acute Parkinsonism complicated with hyperparathyroidism and nephrogenic diabetes insipidus: Report of a case. Acta Neurol Taiwan. 2007;16:231-233.
26. Lecamwasam D, Synek B, Moyles K, et al. Chronic lithium neurotoxicity presenting as Parkinson's disease. Int Clin Psychopharmacol. 1994;9:127-129.
27. Bhattacharjee S, Yela R, Chadwick G. Can lithium unmask the preclinical Parkinsonian features? Ir Med J. 2013;106:254.
28. Cohen WJ, Cohen NH. Lithium carbonate, haloperidol, and irreversible brain damage. JAMA. 1974;230:1283-1287.
29. Juhl RP, Tsuang MT, Perry PJ. Concomitant administration of haloperidol and lithium carbonate in acute mania. Dis Nerv Syst. 1977;38:675-676.
30. Garfinkel PE, Stancer HC, Persad E. A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania. J Affect Disord. 1980;2:279-288.
31. Yee OK. A case of persistent tardive dyskinesia in bipolar mania. Journal of Mood Disorders. 2013;3:128-130.
32. Ghadirian AM, Annable L, Bélanger MC, et al. A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. J Clin Psychiatry. 1996;57:22-28.
33. van Harten PN, Hoek HW, Matroos GE, et al. Evidence that lithium protects against tardive dyskinesia: The Curaçao Extrapyramidal syndromes study VI. Eur Neuropsychopharmacol. 2008;18:152-155.
34. Brandt-Christensen M, Kvist K, Nilsson FM, et al. Treatment with antidepressants and lithium is associated with increased risk of treatment with antiparkinson drugs: A pharmacoepidemiological study. J Neurol Neurosurg Psychiatr. 2006;77:781-783.
35. Pachet AK, Wisniewshi AM. The effects of lithium on cognition: An updated review. Psychopharmacology (Berl). 2003;170:225-234.
36. Kusumo KS, Vaughan M. Effects of lithium salts on memory. Br J Psychiatry. 1977;131:453-457.
37. Ghadirian AM, Engelsmann F, Ananth J. Memory functions during lithium therapy. J Clin Psychopharmacol. 1983;3:313-315.
38. Weingartner H, Rudorfer MV, Linnoila M. Cognitive effects of lithium treatment in normal volunteers. Psychopharmacology (Berl). 1985;86:472-474.
39. Terao T, Nakano H, Inoue Y, et al. Lithium and dementia: A preliminary study. Prog Neuropyschopharmacol Biol Psychiatry. 2006;30:1125-1128.
40. Nunes PV, Forlenza OV, Gattaz WF. Lithium and the risk of Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry. 2007;190:359-360.
41. Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. Curr Alzheimer Res. 2013;10:104-107.
42. ClinicalTrials.gov. Effects of lithium and divalproex in Alzheimer's disease. http://clinicaltrials.gov/ct2/show/NCT00088387?term=lithium+and+alzheimer&rank=2NLMIdentifier:NCT00088387. Accessed March 27, 2014.
43. ClinicalTrials.gov. Efficacy and safety of two pharmacologic strategies on neurocognitive impairment in HIV infection. The TRIANT-TE study. http://clinicaltrials.gov/ct2/show/NCT01348282?term=NCT01348282.&rank=1 Accessed March 31, 2014, .
44. ClinicalTrials.gov. Neuroprotective effects of lithium in patients with small cell lung cancer undergoing radiation therapy to the brain. http://clinicaltrials.gov/ct2/show/NCT01553916?term=NCT01553916&rank=1. Accessed March 27, 2014.
45. Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. Curr Alzheimer Res. 2013;10:104-107.